淋巴瘤患者长期随访的死亡原因分析
|
摘要
淋巴瘤患者的预后相对较好,经规范化治疗后,大部分患者可能长期生存。通过对淋巴瘤患者的长期随访,发现部分患者与治疗相关的远期并发症,通过对淋巴瘤患者死亡原因的分析,有利于进一步改善其预后。本文旨在通过综述淋巴瘤患者长期随访所知的死亡原因进行分析,从而为今后淋巴瘤患者的随访和治疗带来新的思路。
The prognosis of lymphoma patients is relatively good, and most patients may survive for a long time after standard treatment.Long-term follow-up of lymphoma survivors may reveal some late complications related to the treatment. Analysis of the causes of death is helpful in further improving the prognosis of lymphoma patients. The purpose of this article is to review the causes of death in patients with lymphoma during long-term follow-up to generate new ideas for follow-up and treatment of lymphoma patients.
The prognosis of lymphoma patients is relatively good, and most patients may survive for a long time after standard treatment.Long-term follow-up of lymphoma survivors may reveal some late complications related to the treatment. Analysis of the causes of death is helpful in further improving the prognosis of lymphoma patients. The purpose of this article is to review the causes of death in patients with lymphoma during long-term follow-up to generate new ideas for follow-up and treatment of lymphoma patients.
引文
[1]陈万青,李贺,孙可欣,等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2018,40(1):5-13.
[2]石远凯,孙燕,刘彤华.中国恶性淋巴瘤诊疗规范(2015年版)[J].中华肿瘤杂志,2015,37(2):148-158.
[3] Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma[J]. N Engl J Med, 2012, 366(5):399-408.
[4] Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma:10 years of follow-up of the GHSG HD9 study[J]. J Clin Oncol, 2009,27(27):4548-4554.
[5] Matasar MJ, Ford JS, Riedel ER, et al. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood[J].JNCI J Natl Cancer Inst, 2015, 107(4):djv018.
[6] Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease[J]. JAMA, 2003, 290(4):465-475.
[7] Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease[J]. J Natl Cancer Inst, 2002, 94(3):182-192.
[8] Taylor AJ, Croft AP, Palace AM, et al. Risk of thyroid cancer in survivors of childhood cancer:results from the british childhood cancer survivor study[J]. Int J Cancer, 2009, 125(10):2400-2405.
[9] Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Longterm cause-specific mortality of patients treated for Hodgkin's disease[J]. J Clin Oncol, 2003, 21(8):3431-3439.
[10] Favier O, Heutte N, Stamatoullas-Bastard A, et al. Survival after Hodgkin lymphoma:causes of death and excess mortality in patients treated in 8 consecutive trials[J]. Cancer, 2009, 115(8):1680-1691.
[11] Lakoski SG, Willis BL, Barlow CE, et al. Midlife cardiorespiratory fitness, incident cancer, and survival after cancer in men:The copper center longitudinal study[J]. JAMA Oncol, 2015, 1(2):231-237.
[12] Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following breast cancer:a systematic review[J]. Bre Cancer Res Tre, 2017, 164(3):537-555.
[13] Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin's lymphoma[J]. J Natl Cancer Inst,2015, 107(4):djv008.
[14] van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment:40-year disease risk[J]. JAMA Int Med, 2015, 175(6):1007-1017.
[15] Zamorano JL, Lancellotti P, Rodriguez Mu?oz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines:The task force for cancer treatments and cardiovascular toxicity of the european society of cardiology(ESC)[J]. Eur Heart J, 2016, 37(36):2768-2801.
[16] van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin's lymphoma:effects of cardiac exposure to radiation and anthracyclines[J]. Blood, 2017, 129(16):2257-2265.
[17] Kiserud CE, Loge JH, Fossa A, et al. Mortality is persistently increased in Hodgkin's lymphoma survivors[J]. Eur J Cancer, 2010, 46(9):1632-1639.
[18] Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma:a report from the german hodgkin study group[J].Blood, 2014, 123(11):1658-1664.
[19] Eichenauer DA, Becker I, Monsef I, et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma:a systematic review and meta-analysis of randomized clinical trials[J]. Haematologica, 2017, 102(10):1748-1757.
[20] Avilés A, Díaz-Maqueo JC, García EL, et al. Late lethal events in patients with diffuse large B cell lymphoma:A review of 714 patients treated in a single centre[J]. Leuke Lymph, 2001, 42(4):631-637.
[21] Mounier N, Heutte N, Thieblemont C, et al. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial[J]. Clin Lymph Myel Leuke, 2012,12(3):151-154.
[22] Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality,cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy cra[J]. Cancer, 2017, 123(17):3222-3225.
[23] Tsai HT, Pfeiffer RM, Warren J, et al. The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma[J]. Leuk Lymph, 2015, 56(3):682-687.
[24] Marks MA, Engels EA. Venous thromboembolism and cancer risk among elderly adults in the United States[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(9):774-783.
[25] Limat S, Daguindau E, Cahn JY, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma[J]. J Clin Pharm Ther, 2014, 39(5):168-174.
[26] V?kev?L, Lipsanen T, Sintonen H, et al. Morbidity and causes of death in patients with cutaneous T-cell lymphoma in finland[J]. Acta Dermato-Venereol, 2017, 97(6):735-738.
[27] Barzenje DA, Holte H, Foss?A, et al. Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma[J]. Leuke Lymph, 2016, 58(3):623-632.
[28] Bhatt VR, Vose JM. Hematopoietic stem cell transplantation for nonHodgkin lymphoma[J]. Hematol Oncol Clin North Am, 2014,(28):1073-1095.
[29] Bhatt VR, Loberiza FR, Jing H, et al. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades[J]. Clin Lymph Myelo Leuk, 2015, 15(7):409-415.
[2]石远凯,孙燕,刘彤华.中国恶性淋巴瘤诊疗规范(2015年版)[J].中华肿瘤杂志,2015,37(2):148-158.
[3] Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma[J]. N Engl J Med, 2012, 366(5):399-408.
[4] Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma:10 years of follow-up of the GHSG HD9 study[J]. J Clin Oncol, 2009,27(27):4548-4554.
[5] Matasar MJ, Ford JS, Riedel ER, et al. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood[J].JNCI J Natl Cancer Inst, 2015, 107(4):djv018.
[6] Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease[J]. JAMA, 2003, 290(4):465-475.
[7] Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease[J]. J Natl Cancer Inst, 2002, 94(3):182-192.
[8] Taylor AJ, Croft AP, Palace AM, et al. Risk of thyroid cancer in survivors of childhood cancer:results from the british childhood cancer survivor study[J]. Int J Cancer, 2009, 125(10):2400-2405.
[9] Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Longterm cause-specific mortality of patients treated for Hodgkin's disease[J]. J Clin Oncol, 2003, 21(8):3431-3439.
[10] Favier O, Heutte N, Stamatoullas-Bastard A, et al. Survival after Hodgkin lymphoma:causes of death and excess mortality in patients treated in 8 consecutive trials[J]. Cancer, 2009, 115(8):1680-1691.
[11] Lakoski SG, Willis BL, Barlow CE, et al. Midlife cardiorespiratory fitness, incident cancer, and survival after cancer in men:The copper center longitudinal study[J]. JAMA Oncol, 2015, 1(2):231-237.
[12] Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following breast cancer:a systematic review[J]. Bre Cancer Res Tre, 2017, 164(3):537-555.
[13] Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin's lymphoma[J]. J Natl Cancer Inst,2015, 107(4):djv008.
[14] van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment:40-year disease risk[J]. JAMA Int Med, 2015, 175(6):1007-1017.
[15] Zamorano JL, Lancellotti P, Rodriguez Mu?oz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines:The task force for cancer treatments and cardiovascular toxicity of the european society of cardiology(ESC)[J]. Eur Heart J, 2016, 37(36):2768-2801.
[16] van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin's lymphoma:effects of cardiac exposure to radiation and anthracyclines[J]. Blood, 2017, 129(16):2257-2265.
[17] Kiserud CE, Loge JH, Fossa A, et al. Mortality is persistently increased in Hodgkin's lymphoma survivors[J]. Eur J Cancer, 2010, 46(9):1632-1639.
[18] Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma:a report from the german hodgkin study group[J].Blood, 2014, 123(11):1658-1664.
[19] Eichenauer DA, Becker I, Monsef I, et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma:a systematic review and meta-analysis of randomized clinical trials[J]. Haematologica, 2017, 102(10):1748-1757.
[20] Avilés A, Díaz-Maqueo JC, García EL, et al. Late lethal events in patients with diffuse large B cell lymphoma:A review of 714 patients treated in a single centre[J]. Leuke Lymph, 2001, 42(4):631-637.
[21] Mounier N, Heutte N, Thieblemont C, et al. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial[J]. Clin Lymph Myel Leuke, 2012,12(3):151-154.
[22] Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality,cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy cra[J]. Cancer, 2017, 123(17):3222-3225.
[23] Tsai HT, Pfeiffer RM, Warren J, et al. The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma[J]. Leuk Lymph, 2015, 56(3):682-687.
[24] Marks MA, Engels EA. Venous thromboembolism and cancer risk among elderly adults in the United States[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(9):774-783.
[25] Limat S, Daguindau E, Cahn JY, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma[J]. J Clin Pharm Ther, 2014, 39(5):168-174.
[26] V?kev?L, Lipsanen T, Sintonen H, et al. Morbidity and causes of death in patients with cutaneous T-cell lymphoma in finland[J]. Acta Dermato-Venereol, 2017, 97(6):735-738.
[27] Barzenje DA, Holte H, Foss?A, et al. Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma[J]. Leuke Lymph, 2016, 58(3):623-632.
[28] Bhatt VR, Vose JM. Hematopoietic stem cell transplantation for nonHodgkin lymphoma[J]. Hematol Oncol Clin North Am, 2014,(28):1073-1095.
[29] Bhatt VR, Loberiza FR, Jing H, et al. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades[J]. Clin Lymph Myelo Leuk, 2015, 15(7):409-415.